

# All.Can at five years: annual report 2021

All.Can International is a not-for-profit organisation (ASBL) registered in Belgium. Its work is made possible with financial support from Bristol Myers Squibb (sustaining partner) and Roche, MSD, Johnson & Johnson, Baxter and Illumina (funding members).

# Mission

All.Can is the global multi-stakeholder platform for cancer care efficiency, aiming to improve health outcomes for cancer patients around the world.

We collaborate to advance efficiency in cancer care for the benefit of patients and society.

We do so by generating, promoting and advocating for evidence-based and measurable improvements in cancer care research, policy and practice.

## Vision

We imagine a world in which patients are always at the heart of cancer care.

We work together for efficient, equitable and sustainable cancer care that focuses on what matters to patients and society.

# All.Can's work is guided by three Key Principles:



 Put patients first - Define and deliver cancer care efficiency according to what matters most to patients and society.



Adopt a whole-system perspective - Eliminate inefficiencies across the entire cancer care pathway and spectrum.



 Promote multi-stakeholder collaboration - Harness the strengths of all cancer care stakeholders.



12/04/2022 13:35:37



# **Contents**

Section 01	Foreword	5
Section 02	Highlights in 2021	6
Section 03	All.Can's Definition of Efficient Cancer Care	8
Section 04	All.Can's Strategic Roadmap 2022-25	9
Section 05	Key Activities	10
Section 06	External Engagement	15
Section 07	Collaborations	16
Section 08	All.Can in the Media	18
Section 09	Members	19
Section 10	National Initiatives	20



# All.Can's Key Achievements in 2021

#### **Evidence Generation & Thought Leadership**



- Policy report on "Harnessing data for better cancer care"
- All.Can's Definition of Efficient Cancer Care
- 40 Case studies on the Efficiency Hub
- 10+ Articles and publications on efficiency issues

#### **External Engagement**



- All.Can Global Summit: 200+ Participants 14 Speakers
- All.Can Speakers / Representation at 10+ international Events
- 7 Statements and submissions to decision makers consultations
- All.Can Social Media Followers: 1194 on Twitter 680 on LinkedIn 290 on Facebook

#### Global Collaboration & Dissemination



- 18 All.Can National Initiatives
- 30 Organisation and Individual Members
- Collaborating Partners (UICC, ECO, EAVH, EU Health Coalition, SPCC, iPAAC)
- 10 Webinars (in collaboration with SPCC)

#### **Operational Excellence**



- Roadmap 2022-2025: 3 Goals and 6 Strategic Objectives
- 1st Board Election and Annual General Meeting
- 20 Board and Working Group Meetings
- Ongoing Membership relations and monthly communications



## **Foreword**

Section

All.Can International can proudly look back at an eventful and exciting 2021. In its fifth year of existence – and second year since the establishment as a non-profit association - our organisation has actively left its mark in the field of cancer care globally as never before. Despite the ongoing global COVID-19 pandemic we managed to achieve numerous milestones in our work towards efficient, equitable and sustainable cancer care that focuses on what matters to patients and society.

Under the guidance of the All.Can Board, and thanks to the dedicated efforts of the Research and Evidence, Public Affairs and National Initiatives Working Groups and specific Task Forces, All.Can delivered several important outputs and further strengthened its thought leadership towards achieving sustainable healthcare solutions for people affected by cancer.

The foundation of our mission, All.Can's definition of efficient cancer care. was adapted to provide more depth and disseminated widely at the beginning of the year. External engagement activities have increased significantly in 2021, with All. Can providing input into policymaking on several occasions and with All.Can representatives presenting the organisation, its activities and achievements at numerous meetings and events. The All.Can Global Summit, held as a virtual event in May, and the simultaneous launch of the policy report 'Harnessing data for better care' were undoubtful two main highlights in the past twelve months. The second half of the year saw the kick off of the development of the policy blueprint 'Building efficiency in cancer care', as well as the policy research on Efficiency Metrics - which will be delivered in 2022.

All.Can grew its multi-stakeholder membership further in 2021, now counting 30 affiliated organisations and individuals that represent patient advocates, healthcare professionals, industry representatives, academics and researchers alike. In addition, All. Can national initiatives have been formed in 18 countries, with the addition of Colombia, Israel and South Korea, committed

to bringing the All.Can mission into local context.

2021 was also the first year for All.Can International to assemble its first Annual General Meeting with the entire membership, and to hold the first official elections of the Board of Directors. The not-for-profit legal entity established in 2020 further consolidated its governance and internal functioning by producing comprehensive Internal Regulations that complement the stipulations of the Articles of Association.

In less than five years, All.Can has developed rapidly into a truly international, multi-stakeholder platform. To ensure sustainable and impactful growth, the organisation has embarked on a review of its strategic framework and a consultation with members, funders and national initiatives on priorities and opportunities, which have led to the development of a coherent roadmap for the coming years.

We would like to thank the All.Can membership, national initiatives and wider community for their hard work and dedication during this successful past year. Together we are building a true community of practice are stronger in achieving our mission!



**Alex Filicevas** President. All.Can International



**Eduardo Pisani** Chief Executive Officer, All.Can International



# Highlights in 2021



Feb

All.Can Statement for World Cancer Day

All.Can Feedback on European Health Data Space



New All.Can National Initiatives launch in Colombia and Israel

All.Can speaks at Pacific Association for the Study of the Liver Conference



Mar

All.Can @4 Annual Report

All.Can speaks at DIA Europe

Pancreatic Cancer Europe joins as new member

**(** 



**Apr** 

All.Can's Definition of Efficiency in Cancer Care

All.Can holds its first Elections and General Assembly

May

Launch of All.Can Data Report

All.Can Global Summit



Jun

All.Can speaks at European Patient Rights Day Event



## Aug

All.Can joins the

Union for International **Cancer Control** 



Sep

**(** 

All.Can speaks at Fortune Health Italia



**(** 

Jul

All.Can joins the European Health Value

Alliance

Oct

All.Can participates in TEHDAS Stakeholder and **Project Fora** 



Nov

All.Can speaks at The Economist **World Cancer Series** 

All.Can speaks at EuropeanCancer Summit





Dec

All.Can participates in iPAAC Final Conference





# All.Can's Definition of Efficient Cancer Care

Efficient cancer care delivers the best possible health outcomes using the human, financial, infrastructural and technological resources available, with a focus on what really matters to patients and society.

In early 2021, All.Can published its updated definition illustrating what efficient cancer care means, why it matters and how it can be achieved across the entire care continuum and at different system levels. To support the dissemination of the updated efficiency definition, a video and an infographic were developed and circulated widely in the community.







Keeping patients and societal outcomes as a north star, All.Can has continued to build on strong foundations, launching in new geographies, sharing best practices for efficient cancer care and embarking on unique partnerships to drive data and expand the reach of our policy recommendations. Today we have a robust, evidence-based definition of efficiency in care that can be measured, which will bring to life the value of our work for patient and societal outcomes. As a member of the All.Can Board, I believe our strength comes from the truly multidisciplinary representation from patient organizations, policymakers, healthcare professionals, researchers and industry, each bringing their unique expertise and passion, with an unwavering focus on achieving sustainable, efficient, patient-centred care for all."

#### **Amadou Diarra**

Bristol Myers Squibb - Member of the Board 2021






# All.Can's Strategic Roadmap 2022-25

Section 0**4** 

All.Can has been developing rapidly from a small community of interest to a truly international, multi-stakeholder association in just a few years. To make its growth sustainable and guide its progress towards achieving true impact, All.Can engaged in a thorough strategic planning process aimed at creating a multi-annual roadmap.

Co-developed with members and National Initiatives, the roadmap ensures that All.Can's work is routed in a shared understanding of the association's purpose and priorities, which offers a solid framework and clear direction to All.Can leaders and decision-makers, as well as representing a means to measure impact and progress. To identify key priorities for All.Can in the next years, the association's purpose and strategic framework were updated, resulting in a three-pillar virtuous circle model that puts patients in the centre.

By evaluating past activities and identifying new opportunities, All.Can members and National Initiatives identified concrete, time-bound activities and targets to advance its strategic objectives in the coming years. Presented in a visual All.Can Roadmap for 2022-2025, the strategic narrative for driving impact, development and growth becomes evident.







It has been a real honour to join the Board of All.Can in the last year and witness closely the tremendous work done by the small but agile team in collaboration with the amazing network of national All.Can initiatives. With an effective strategic plan the organisation has published an influential report on data, showcased examples of efficient cancer care, organised a very successful on-line conference and brought on new national groups. We are now planning a raft of new activities including developing an efficiency metric for cancer care, a health literacy project collaboration and finalising a second policy report. My local Australian All.Can group has developed a cancer navigator model and is planning its implementation."

#### **Professor Christobel Saunders**

University of Melbourne - Vice-President of the Board 2021, Co-Chair of the Research & Evidence Working Group 2021

--



# **Key Activities**

## All.Can Global Summit

Improving efficiency in cancer care through multi-stakeholder collaboration

27 MAY 2021 | 15:00-17:15 (CEST)



#### **All.Can Global Summit**

On 27 and 28 May 2021, All.Can held its virtual Global Summit entitled 'Improving Efficiency in Cancer Care Through Multi-Stakeholder Collaboration'.

The policy-oriented, external meeting of 27 May was attended by over 200 participants from 37 countries and saw the launch of the new All.Can data report, 'Harnessing data for better cancer care'. Various panels, which featured experts from the World Health Organisation (WHO) and the Organisation for Economic Co-operation and Development (OECD), as well as patient representatives, healthcare professionals, and industry players, explored opportunities to drive efficiency in cancer care and achieve the best possible health outcomes, examined how to optimally use data in cancer care, and discussed policies and practices needed to drive efficiency.

On 28 May, two internal meetings were organised with All.Can's Members and National Initiatives, who had the opportunity to interact, get to know each other and share experiences in virtual networking sessions, participate in polls to identify common priority areas, and attend focused breakout sessions on the topics of supportive care and harnessing data for better cancer care.

#### **Summit Speakers:**

- Abdullahi Sheriff AVP, Global Leader, Affordability and Sustainable Access Solutions, MSD
- Alex Filicevas President, All.Can International and Executive Director, World Bladder Cancer Patient Coalition
- Amadou Diarra Senior Vice President Global Policy & Government Affairs, BMS
- Antonella Cardone Board Member, All.Can
   International and Director, European Cancer Patient
   Coalition
- Christobel Saunders Research and Evidence WG co-Chair and Board member, All.Can International and Professor of Surgical Oncology, University of Melbourne
- Dipak Kalra President The European Institute for Innovation through Health Data
- Gregory Katz Professor, Chair of Innovation and Value in Health, Université de Paris

- Kathy Oliver Chair and Founding Co-Director, The International Brain Tumour Alliance
- Matthew Hickey Research & Evidence WG co-chair, All.Can International and Chief Executive Officer, The Health Value Alliance
- Matti Aapro Board Member, All.Can International, President, European Cancer Organisation and Board Member, Clinique de Genolier
- Niek Klazinga Head of the Health Care Quality Indicator Programme, OECD
- Roberta Ortiz Global Initiative for Childhood
   Cancer Medical Officer, World Health Organization
- Suzanne Wait Managing Director, Health Policy Partnership
- Vivek Muthu Managing Director, Marivek Healthcare Consulting

Section 0**5** 







We know that improving efficiency in cancer care with patients at its heart is only achievable through meaningful collaboration with all stakeholders. That's why the All.Can Global Summit was a significant milestone — with actionable discussions and the launch of the data paper. Our National Initiatives came together to share knowledge and exchange ideas on bringing this mission to different corners of the world. As our All.Can family grows, so does our collective role in driving muchneeded change in cancer care for patients and society."

#### **Alex Filicevas**

World Bladder Cancer Patient Coalition -President of the Board 2021, Co-Chair of the National Initiatives Working Group 2021

# Policy Report 'Harnessing data for better cancer care'

All.Can's new policy report 'Harnessing data for better cancer care' was officially launched at the All.Can Global Summit on 27 May 2021. Assessing the essential role of data in cancer care to improve outcomes for all people with cancer, the report makes recommendations to overcome the main barriers to fully harnessing the immense potential of data to transform cancer care, including data siloes, a lack of interoperability, unclear actionability of existing data, complex data governance, and limited ability to re-use data for other purposes.

With the report, All.Can calls on policymakers to consider data both as an investment and an innovation, and highlights that having the correct data systems in place that enable the analysis and extraction of meaningful insights to guide decision-making, is as important to the future of cancer care as new medicines and other advances.

The report was distributed widely in the international cancer community and received widespread public coverage and recognition.







#### Webinar series

Spotlights on Improving Efficiency in Cancer Care The webinars are part of a larger research and educational programme in collaboration with All.Can and SDA Bocconi School of Management.



Held in collaboration with



#### **CME-Accredited Webinars**

In late 2020, Sharing Progress in Cancer Care (SPCC), in partnership with All.Can, launched a CME-accredited webinar series on 'Spotlights on improving efficiency in cancer care'.

The collaboration was continued successfully throughout 2021, with the organisation of ten webinars aiming at content development to underpin the delivery of efficient cancer care.

- 13 January Moving towards efficiency: examples
- 10 February Optimisation and efficiency in cancer care
- 17 March What is efficiency in Latin America?
- 12 April What is efficiency in cancer care in Australia?
- 12 May What is efficiency in Japan & Korea?
- 23 June The case of caregivers
- 6 September The potential of data to improve efficiency in cancer care
- 25 October Examples of best practice from the All.Can Efficiency Hub (I)
- 24 November Examples of best practice from the All.Can Efficiency Hub (II)
- 15 December Efficiency in the Europe's Beating Cancer Plan



I am delighted to look back at the work done by All.Can in the past year and see so many achievements while sharing our common vision for a Europe, where health systems are value-based, sustainable, and people-centred. During the challenging year of 2021, together with All.Can, we examined the inefficiencies of the healthcare systems, and derived lessons on how to ensure the sustainability of health systems and ultimately deliver better care for cancer patients."



#### **Antonella Cardone**

**European Cancer Patient Coalition** 

- Member of the Board 2021











All.Can has developed a vision to improve the efficiency of cancer care by putting the needs of patients at the core of all its political and public engagement activities. By enabling dialogue and providing concrete solutions, All. Can has paved the way towards better health outcomes for cancer patients and long-term sustainable health systems. As a health professional, policy advisor and patient advocate, I am delighted to see how this initiative has brought added value to the cancer policy debate globally."


#### Adela Maghear

European Cancer Patient Coalition – Co-Chair of the Public Affairs Working Group 2021

# **Best Practice Examples in the Efficiency Hub**

All.Can's Efficiency Hub, an online collection of examples of best practice in cancer care, continued to grow further in 2021. Covering the entire cancer care pathway as well as all types of cancer, the case studies are readily accessible to all and provide value to the global cancer stakeholders by creating a learning community and helping organisations to find and implement solutions to common challenges.

Launched in 2019, the Efficiency
Hub counts 40 examples of efficient
practices in cancer care. Its geographical
scope has been expanded beyond
Europe and the United States, to feature
case studies now also from low- and
middle-income contexts. For its third
anniversary in 2022, an 'Efficiency Hub
think piece' will be produced, in which
the existing examples will be reviewed
and explored for common features and
trends, as well as their demonstrated
impact on efficiency in cancer care.









Two major outputs will be delivered in the first half of 2022:

# Policy Blueprint 'Building efficiency in cancer care'

Our new policy blueprint 'Building efficiency in cancer care' will update All.Can's inaugural policy report from 2017 in light of new evidence and developments, as well as the impact of the COVID-19 pandemic. The document will include recommendations aimed at decision-makers for adaptation according to the specific national or local situation and showcase examples of good practice from the All.Can Efficiency Hub and elsewhere to encourage their wider adoption.

### **Efficiency Metrics Policy Research**

A collaborative policy research project aimed at developing a standard set of metrics to measure cancer care efficiency based on a validated definition, will be executed in early 2022. Conducted jointly by The Health Value Alliance, the University of Southampton and All.Can International, the project's goals are to identify the core 'real-world' measures associated with 'efficiency', to provide sound evidence as justification for these measures, and to produce a standard set of measures, contained in a policy report for public dissemination and use by All.Can.





All.Can's is serving a vital role in developing and socialising insights into some of the core challenges in cancer care, specifically from the patient perspective. All'Can's collaboration with patients and multiple industry stakeholder is pivotal in ensuring we all work together and play our part in developing person-centred, evidence-based and sustainable cancer care, globally."

#### **Matt Hickey**

The Health Value Alliance - Co-Chair of the Research & Evidence Working Group 2021







# **External Engagement**

On the occasion of **World Cancer Day** on 4 February, All.Can published a statement calling for sustainable cancer care policies that give the greatest benefit to patients and value to the wider system.

Also in February, All.Can provided feedback on the European Commission's **European Health Data Space** (EHDS), welcoming the initiative to ensure access and optimal use of health data, as well as digital health products and services in Europe. In the statement, All.Can called attention to several challenges and proposed recommendations to ensure a comprehensive EHDS that has patients' needs at its core and can help create a cycle of continuous improvement driving accountability across the entire care pathway.

On **World Health Day**, 7 April, the European Cancer Patient Coalition, member of All. Can, launched a global campaign on the **Joint letter on COVID-19 and cancer** to urge policymakers to identify and mitigate the impact of the global pandemic on cancer services. It was signed by 320 cancer stakeholders, including All.Can. On 19 July, All.Can joined a meeting with the World Health Organisation (WHO) to explore how the letter co-signatories can best collaborate with WHO.

On 21 April, All.Can participated in the **G20 Global Health Summit** Consultation with Civil Society
Organisations on Sustainable Health Security
Preparedness and Response, and submitted
recommendations for improving efficiency in cancer
care and across healthcare systems more broadly for
consideration in the drafting of the Summit's outcome
document, the Rome Declaration.

On 16 June, All.Can representatives spoke about efficiency in cancer care at the high-level policy meeting "The Fight Against Cancer: A Challenge for the European Health Union" organised by the European Committee of the Regions (CoR) Interregional Group on Health & Wellbeing, which brought together national authorities, MEPs, European Commission officials, experts and representatives of stakeholder organisations to discuss the Europe's Beating Cancer Plan and the European strategy in the fight against cancer.

Eduardo Pisani contributed with a video message to the European Cancer Organisation's **Time To Act campaign** launch event in Italy, which took place in June 2021 featuring several high-level speakers.

# All.Can at Events – Speaking Engagements and Participation in 2021:

- 4-6 February, Pacific Association for the Study of the Liver Conference: Calling for an advocacy reset: Treat hepatitis, prevent cancer' – Eduardo Pisani
- 15-19 March, DIA Europe 'Building frameworks to make the promise of personalized healthcare a reality by enabling healthcare systems' – Eduardo Pisani
- 5-6 May, European Patient Rights Day event organized by Active Citizenship Network -
- 21 September, HPP Webinar 'Fostering readiness in cancer care' - Alex Filicevas, Antonella Cardone
- 27-28 September, Fortune Italia Health
   Forum Eduardo Pisani
- 27 October, TEHDAS Stakeholder Forum
- 29 October, TEHDAS Project Forum
- 8-11 November, The Economist World Cancer Series: Europe 2021 – Eduardo Pisani, Alex Filicevas, Antonella Cardone, Christobel Saunders
- 17-18 November, ECO European Cancer Summit – Alex Filicevas
- 13-14 December, iPAAC final conference







### **Collaborations**

In 2021, All.Can became an associate member of the **Union for International Cancer Control** (UICC), which represents over 1200 organisations in 172 countries including the world's major cancer societies, ministries of health and patient groups. UICC unites and supports the cancer community to reduce the global cancer burden, promote greater equity, and ensure that cancer control continues to be a priority in the world health and development agenda.

To reinforce its collaboration with the **European Cancer Organisation** (ECO), an agreement was signed to develop and implement joint activities that support the mission of reducing the burden of cancer, particularly in the area of efficiency, quality and sustainability of cancer care. In early 2022, ECO submitted two project applications to the EU4Health Programme in which All.Can is included amongs the proposed partners: 'HAND-IN-HAND' (Health Literacy among Disadvantaged Groups for Heightened Cancer Prevention and Care Delivery in Europe) and 'smartCARE' (smart Card Application improving canceR survivors' quality of life).

All.Can also joined the **European Alliance for Value in Health** (EAVH) as an affiliate partner. Representing a broad range of stakeholders including patients, scientific and professional societies, healthcare managers and professionals, hospitals, payers and industry, EAVH works towards a shared vision value-based, sustainable, and people-centred health systems in Europe, by facilitating health system transformation, sharing knowledge and best practices, and engaging with policymakers and stakeholders at European, national and regional levels.

All.Can continued its collaboration with the **EU Health Coalition**, which is composed of patient organisations, EU research-oriented medical societies, industry organisations, healthcare providers, regional and local health authorities and other relevant stakeholders, and seeks to ensure that health remains high on the political agenda and champions policy changes to address the unprecedented challenges that an ageing population and an increasing prevalence of chronic diseases pose to healthcare systems and citizens.





Section 0**7** 



2021 also saw the conclusion of the **Innovative Partnership for Action Against Cancer** (iPAAC), a 3-year joint action of the European Commission aiming to define strategies to improve the quality of cancer care by optimising the use of healthcare resources and promoting realistic and evidence-based responses to existing needs. As part of the iPAAC Work Package on 'Challenges in Cancer Care', All.Can contributed to the final deliverable, 'the Roadmap on Implementation & Sustainability of Cancer Control Actions', with real life examples of European Cancer Centres' innovative initiatives to make their organisations more efficient, and better meet patients' needs.





One more Covid year...But in these complex times, the fight against cancer should not decrease. All.Can salutes the European Union's fight against cancer. We are also proud to cooperate with the European Cancer Organization and with Sharing Progress in Cancer Care. But Europe is not the world and cancer strikes everywhere. We salute all the National Initiatives that collaborate with so many stakeholders. All.Can hopes to see more of you joining our efforts in 2022."

**Dr. Matti Aapro**European Cancer Organisation
Vice-President of the Board 2021

--



# All.Can in the Media

Section 08

- Fortune Health Italia magazine published an op-ed by Eduardo Pisani, in which the tremendous potential of data to drive quality, innovation and efficiency across the entire cancer care continuum is highlighted.
- Fortune Health Italia also published an article and released a podcast with Eduardo Pisani, covering the debate he moderated on 27 September on international collaboration to improve the sustainability of health systems and patient outcomes at Fortune Italia Health's Forum Health event.
- Innovation News Network published an article in which Eduardo Pisani discusses All.Can's landmark report.
- **UICC** featured a blog post 'Reducing equity gaps in cancer care through innovation and data' in which Eduardo Pisani presents All.Can's understanding of efficient cancer care and the vital role of data in making equitable access to high-quality care a reality for everyone affected by cancer.
- A report prepared by experts for the **European Commission** to inform the Cancer Mission Board's strategy, 'the Foresight on Demand Brief in Support of the Horizon Europe Mission Board', included a reference to the 2017 inaugural All. Can policy report to highlight the pertinence of improving the efficiency of cancer care.
- Brain Tumor Magazine published an article entitled 'Datadriven efficiency across the cancer care pathway' written by Shannon Boldon and Suzanne Wait (The Health Policy Partnership) on behalf of All.Can International.
- Cancer World magazine published reports of the All.Can-SPCC webinars throughout the year.



All.Can continued to grow its presence on social media in 2021, including the launch of an All.Can-branded YouTube channel that features video content of All. Can International and of All.Can's National Initiatives in the integrated sub-channels.













## **Members**

All.Can International's membership reflects its multi-stakeholder representation and includes experts from patient organisations, policymakers, healthcare professionals, researchers and industry. Its 26 organisational and 4 individual members contribute their unique knowledge and expertise to improve efficiency in cancer care, act as ambassadors for All.Can, help to publicise its work, events, publications and research findings.





















































All.Can International receives funding from Bristol Myers Squibb (sustaining partner), Johnson & Johnson, Roche, MSD, Baxter and Illumina (funding members). Additional financial support for projects has been provided by Amgen and Novartis.







Agnieszka Krukowska-Van Handenhove Johnson & Johnson - Co-Chair of the Public Affairs Working Group 2021

All Can at 5 A4 js.indd 19 12/04/2022 13:35:40













# **Argentina**

#### **Achievements 2021**

All.Can Argentina published its first scientific paper, "Qualitative Study on Barriers To Access From The Perspective of Patients and Oncologists" that is based on the results of its cancer patient survey, in the International Journal of Innovative Science and Research Technology (IJISRT). In collaboration with UCASAL and Universidad de San Andrés, the National Initiative carried out two editions of the "Health Literacy Seminar for Oncologists" that focused on communication with patients and received great feedback from attendees. As part of its oncology training program, All.Can Argentina produced five new videos around oncohematology, and uploaded another four new video capsules about oncology nursery in its YouTube channel. Furthermore, the National Initiative sponsored the very successful free download book "Demystify cancer" that covers the divers cancer patient experiences. Together with IPSOS, it designed and launched its second cancer patient survey that is inspired by the PaRIS questionnaire used

cancer patient survey that is inspired by the PaRIS questionnaire used by OECD and has the key aim of understanding the general well-being of cancer patients in Argentina. The National Initiative launched new local social media channels on Twitter and LinkedIn, and conducted different internal trainings to empower its Steering Committee in the areas of digital communication, rhetoric and legislation.

#### Outlook 2022

In 2022, All.Can Argentina will focus on increasing its visibility and communicating about the results of the new patient survey. The National Initiative will continue its oncology training program and release of material to key medical audiences, as well as the production of a new series based on screening programs. A new research study around burnout in oncology nursery is being initiated, which will evaluate the physical, emotional, and behavioural symptoms that might interfere with the high care requirements of cancer patients, and investigate the negative aspects on the quality of personal, family and professional life, with the ultimate goal to design possible strategies to prevent or minimize them. In line with its plan to enhance visibility with stakeholders, All.Can Argentina has established contact with OECD when designing the new patient survey, and has been invited to participate in the PaRIS Breast Cancer PROMs Working Group. Furthermore, the National Initiative has already taken first steps towards the creation of an All.Can regional hub.





# \* \* \*

# **Australia**

#### **Achievements 2021**

Throughout 2021, All.Can Australia focused its efforts on progressing its project into cancer care navigation in partnership with Healthcare Management Advisors (HMA). The All.Can Australia Cancer Care Navigator Analysis Report was launched in November 2021, outlining the potential benefits of establishing Australia's first universal cancer care navigation model to help guide those diagnosed with cancer, regardless of cancer type, demographic or location, through Australia's complex health system. This novel approach proposed by All.Can Australia has been designed to drive equitable access to cancer services, make the best use of existing resources and address a critical unmet need. Recognised as a national priority area, cancer navigation has been raised at a recent Cancer Australia Ministerial Roundtable. All. Can Australia and HMA's research concluded that pan-cancer care navigation may be able to deliver multiple patient, health system and economic benefits. The model could generate annualised savings of AU\$46 million per year or AU\$900 per patient, representing a return on investment of 44% based on the overall service cost. The National Initiative has begun discussions about piloting the model, which may provide the opportunity to work with government and other stakeholders to co-design the pilot and oversee its delivery in a select jurisdiction.

#### Outlook 2022

All.Can Australia will focus on driving better awareness and interest in the proposed cancer care navigation pilot. Continued discussions with State and Federal governments will provide clarity on its scale and design. All.Can Australia will also continue conversations with patient and consumer organisations who have similar navigation programmes in place or in planning.

2022 also represents the year that All.Can Australia will become a legal entity. The plans to restructure are in its final stages and new contacts are being made to attract additional members. The move to become a standalone organisation will open doors for funding, collaboration and advocacy work.

All.Can Australia also plans to continue exploring opportunities for collaboration with other All.Can National Initiatives. As a start, an introductory meeting has been held with All. Can UK to learn more about their current focus and priorities, and to share experiences to help both initiatives to progress further. All.Can Australia is also looking into commencing new projects that will target some of the other 'pain points' that have been identified through the 2018 global patient survey.











## **Austria**

#### **Achievements 2021**

All.Can Austria's main event in 2021 was the press conference held on 3 November at the Presseclub Concordia in Vienna, marking the first public appearance of the National Initiative and providing the opportunity to give an overview of its aims and activities, as well as a specific presentation of its scientific tumor board study.

The National Initiative held official elections and set up an extended Steering Committee, and developed and approved a new strategy paper and terms of reference. Furthermore, a website dedicated to All.Can Austria has been launched, and first steps have been taken with regards to the realisation of a patient survey in Austria.

#### Outlook 2022

In 2022, All.Can Austria's work will focus on the conduction of the cancer patient survey, with the plan to present the results in the first half of the year.

The National Initiative also plans to organise an open space event with many stakeholders from the cancer field, and will engage in outreach activities to political stakeholders.



All.Can Austria press conference, Nov. 2021





# Belgium

#### **Achievements 2021**

A major milestone for All.Can Belgium in 2021 was its successful transformation to a non-profit organisation recognised by Belgian law. This new legal structure allows All. Can Belgium to professionalise its governance and to solidify its presence in the Belgian cancer landscape. As an established non-profit organisation, All.Can Belgium has attracted new members in line with its unique multi-stakeholder principle.

In parallel, All.Can Belgium organised various internal workshops to define the mission, set priorities and develop its strategy. Early in the year the first official kick-off meeting was held with the OPTIMOC team (Optimisation of Multidisciplinary Oncology Consultation in Belgian Oncology Departments). It was an inspiring and promising start of the project that examines ways to improve patient-centred treatment decision-making for cancer patients, and is due to deliver its first results in 2022.

Similarly, the youth early diagnosis project was launched and a first kick-off meeting was held with Belgian clinicians across the country and across various disciplines to align on the medical strategy. This set the important medical foundations for the project which aims to raise awareness on early diagnosis for breast cancer, testicular cancer and sarcoma among younger patients.

#### Outlook 2022

Looking ahead to 2022, All.Can Belgium is excited to continue to grow as a non-profit organisation, welcome new members, discover OPTIMOC's preliminary results and to launch the awareness campaign on early diagnosis for the youth.



The National Initiative also looks forward to translating the inspiring Europe's Beating Cancer Plan into Belgian needs and actions by adopting our multi-stakeholder approach to enrich the debate and develop concrete solutions for cancer patients.










## Canada

#### **Achievements 2021**


In 2021, All.Can Canada completed a research project on the current state of cancer diagnosis in Canada and completed a corresponding report 'Optimizing Diagnosis in Canadian Cancer Care', which shares the key findings and gives recommendations to improve the cancer diagnosis for people in Canada. All.Can Canada presented the results at the North American Conference on Integrated Care (NACIC) in October 2021. In addition, the National Initiative hosted its second multi-stakeholder roundtable meeting to review the research findings and identify opportunities to advance the reports' recommendations.

#### Outlook 2022

In 2022, All.Can Canada will, officially release the report 'Optimizing Diagnosis in Canadian Cancer Care' and execute a knowledge mobilisation plan to engage stakeholders. Furthermore, the National Initiative plans to create a multi-year, strategic action plan, working with opportunities identified at the roundtable meeting as a starting point. To support its strategic plan, All.Can Canada will pursue publication and engagement opportunities, and also assess the need to refresh its governance structure. The National Initiative also intends to convene



a third, multi-stakeholder roundtable meeting to assess progress in implementing policy recommendations, and determine the objectives and action plan to guide the work of All.Can Canada in 2023.







# Colombia

#### **Achievements 2021**

In its first year of existence, All.Can Colombia has already achieved several successes relating to oncological efficiency in the country's health system. Initial steps after the launch included the identification and integration of key multisectoral actors into the initiative, and the planning of actions to give visibility to the issue of cancer efficiency in Colombia.

In collaboration with the National Consulting Center and Colombian Association of Hematology and Oncology, All.Can Colombia conducted a great patient survey, whose outcomes were presented to the National Government, specifically to the Direction of the Ten-Year Public Health Plan (2022-2031). The survey was elaborated in two phases: the quantitative phase consisted of a sampling frame of 800 patient surveys, while during the qualitative phase 40 in-depth interviews were conducted with service providers, insurers, medical specialists and caregivers, to learn other perspectives on opportunities to improve efficiency of the oncology health system.

All.Can Colombia also worked on building and strengthening its international relations. Several meetings were organised with world experts in cancer efficiency, in order to introduce All.Can's definition of efficiency, as well as experiences of regional referents in the context of the All.Can Efficiency Hub. The 'Virtual Forum on Cancer Efficiency' was held on 24 November, with the presentation of Prof. Manuel Garcia, an international expert in cancer efficiency, and the participation of several actors from the Colombian health system, such as the Director of the Ten-Year Public Health Plan (2022-2031), Dr. Carlos Pinzon.

Finally, All.Can Colombia has worked on the development of a paper on cancer efficiency, which compiles information on the existing literature on the subject and which will be made publicly available on specialised websites from 2022.

#### Outlook 2022

In 2022, All.Can Colombia is seeking to achieve four strategic objectives: contribute to the design, formulation, evaluation, monitoring and social control of public policies on cancer, particularly the Ten-Year Public Health Plan (2022-2031); contribute to the control of cancer through advocacy in public policies; collaborate with partner organisations to strive for efficiency and equity in cancer; and strengthen the knowledge management to improve the conditions of cancer patients. Other activities for 2022 include the dissemination of the efficiency report on cancer, the organisation of two webinars and the increase of social media activities. The All.Can Colombia coalition is keen to take on the challenges along the way, to generate a better quality of life and life expectancy for cancer patients.











# **Denmark**

#### **Achievements 2021**

In April 2021, All.Can Denmark hosted a big national, digital conference: "Cancer Summit: From symptom to diagnosis – how can we create the best course of treatment for cancer patients in Denmark?". Transmitted and livestreamed directly from the Danish Parliament, the event's purpose was to present the work of All.Can Denmark and create further awareness of the networks' efforts.

Other activities undertaken by the National Initiative include the publication and wide dissemination of an academic report on cancer programs, the establishment of a Steering Committee and the organisation of two network meetings, as well as increased activity on social media.

#### Outlook 2022

All.Can Denmark will continue to focus on early access to treatment and inequality, and will start to increasingly take a look at the topics of health data and technologies.

The National Initiative will organise its first network meeting at the end of January 2022. The 2022 edition of the Cancer Summit will be held on 30 March.

# Cancer Summit: Kan fællesskaber i hverdagen styrke tidlig opsporing?

Den 30. marts kl. 10:00-13:00 i København (lokation følger).



Ulighed i sundhed er et stigende problem i det danske sundhedsvæsen – også når det gælder tidlig opsponing af kræft. His vi for alvor skal reducei ulighed, må vi udfordre vores traditionelle forventning om, at borgerne henvender sig til sundhedsvæsenet, pår syndom rammer.





# Germany

#### **Achievements 2021**

The year 2021 was largely characterized by All.Can Germany's work on the implementation of a model project aimed at improving cancer care in rural areas in Germany. At the beginning of the year, a pilot region was selected following a detailed analysis of five rural areas. In this region around Templin, a small town just outside of Berlin, a stakeholder consortium that looked at enhancing outpatient medical care in rural areas already existed. However, its focus thus far had primarily been on medical areas such as gastroenterology and cardiology, and less on oncological aspects. After All.Can Germany had made an initial contact over the summer, a virtual meeting with representatives of the consortium was organised in the early fall to get to know each other and exchange ideas. A follow-up meeting to discuss more specific aspects of a possible cooperation was to be held at the end of 2021, but had to be cancelled due to the ongoing pandemic.

#### Outlook 2022

In 2022 All.Can Germany will proceed with its work on the rural project and continue the discussions with the consortium of stakeholders in Templin. The second meeting will largely determine the next steps of the potential cooperation between All.Can Germany and the consortium.

In addition, the National Initiative plans to raise awareness and increase its presence in health policy in Germany. To this end, it intends to organise a small side-event at an oncology conference in July 2022 in order to promote its own positions and goals to the public.











# Greece

#### **Achievements 2021**

In 2021, All.Can Greece, in close collaboration with Piraeus and Athens Universities, developed two major White Papers addressing the delays in starting radiation therapy of cancer patients, and the delays between the initial diagnosis and the start of systemic or other cancer treatment. Covering large gaps in tackling current insufficiencies, the reports' policy recommendations are gradually being implemented by the Ministry of Health, such as the expansion of working hours of radiotherapy departments that resulted in a remarkable reduction of delays in the start of radiotherapy. Both White Papers were presented at All.Can Greece's scientific webinar 'The Role of Data in Cancer Care' in July, at a press conference held in October, and in a video launched in November.

In consultation with All.Can Greece members, the Steering Committee prepared a detailed report about the major problems and obstacles faced by cancer patients and clinicians and the impact of the Covid-19 pandemic. In a meeting with Deputy Minister of Health Mr. V. Kontozamanis, the government confirmed its commitment to improve cancer care, taking into consideration the recommendations contained in All.Can Greece's report.

In December, All.Can Greece introduced its activities at the Hellenic Congress for Economics and Health Policies. In the session 'Three Years All.Can Greece', the Steering Committee members and All.Can CEO Eduardo Pisani presented the achievements of the National Initiative to-date and the roadmap ahead. In the same month, a webinar 'Quality & Safety of Health Care Services in Oncology Hospitals' was organised, showcasing the chronic problem of quality and safety of cancer care delivery that deteriorated dramatically during the COVID-19 pandemic, and presenting policy recommendations to address the inefficiencies.







#### Outlook 2022

All.Can Greece has grown to be one of the most reliable interlocutors when it comes to cancer care in Greece. The National Initiative will continue to implement actions with an increased added value for both cancer patients, health care professionals



and the health care system, such as scientific webinars and informational events in oncology hospitals, and direct consultations with the country's major health and social policymakers, notably the Ministry of Health.





# Israel

#### **Achievements 2021**

The All.Can National Initiative in Israel was officially approved in early 2021. Established as a registered independent entity (NPO) in the country, All.Can



Israel set the focus of its first year of work on the involvement of more members to join the initiative, as well as the preparations for the conduction of a cancer patient survey in Israel.

#### Outlook 2022

For 2022, All.Can Israel has planned to proceed with the work on the cancer patient survey. The questionnaire will be finalised with a view to making it relevant to the Israeli Health care environment. All.Can Israel intends to collaborate with a research institute and to publish the results as a study.

Furthermore, All.Can Israel would like to join the efforts of cancer care stakeholders in the country to establish a National Cancer plan in Israel.









# **Italy**

#### **Achievements 2021**

All.Can Italy has produced several outputs in 2021. The National Initiative completed the report on 'Regional disparities in onco-haematology' which indicates areas of improvement of the patient journey in oncohaematology. The study results were shared in a workshop gathering the main stakeholders in this area, during which the policy objectives to pursued with policymakers had been identified. The results of All.Can Italy's in-depth work on oncology and oncohaematology networks have been documented and will be shared with public institutions in view of the country's healthcare reform that is currently in progress.

All.Can Italy has also been involved in studying the best practices of a hospital facility that was able to guarantee COVID-free pathways for patients, as well as exploring experiences in territorialisation and home care, and aims to publish these insights as examples of best practice in the All.Can Efficiency Hub in 2022.

In addition, All.Can Italy has published a study on the impact and opportunities of Europe's Beating Cancer Plan, and contributed to the 'Report on the welfare condition of oncological patients' of the Italian Federation of Voluntary Associations in Oncology by writing a chapter on the implementation of the Europe's Beating Cancer Plan.


#### Outlook 2022

In 2022, All.Can Italy will present the report on onco-haematology and the objectives identified at a conference with policymakers, with a view to start a dialogue aimed at achieving the policy objectives set out in the document.

A further project of the National Initiative will focus on the impact of the National Plan for Recovery and Resilience, the reform of territorial care and the hospital-territory relationship on the new patient journey in oncology.

Moreover, the opportunities arising from Europe's Beating Cancer Plan will form the subject of an in-depth analysis.















#### **Achievements 2021**

All.Can Korea selected 'improving awareness of the importance of psychological support for cancer patients', identified via its patient survey as a key solution, as its principal project for the improvement of inefficiencies in Korea's cancer treatment environment.

In July All.Can Korea held a policy forum 'Unmet needs in cancer care: the solution is in the mind of cancer patients' to propose policies for cancer patient counselling, which was hosted by the research council of Korea's National Assembly 'Well Dying Research Council for a Dignified Life'. The forum saw the intervention of an expert on cancer patient psychological support, the presentation of All.Can Korea's policy proposal for sustainable community-led psychological support services for cancer patients, as well as a panel of various stakeholders such as service providers, expert groups, service recipients, media, and health policy authorities that discussed the need for effective psychological support for cancer patients and exchanged opinions on the proposal's feasibility. The Health and Welfare Committee emphasised the need for psychological support for cancer patients and assured continuous engagement through various methods to support it.

#### Outlook 2022

In 2022, All.Can Korea will conduct research to provide high accessibility to psychological support services for cancer patients. Under the agenda of 'Inter-Patient Mentoring Protocol development for Cancer Patient Psychological Counseling', the aim is to develop a protocol for counseling services through local communities, whereby cancer survivors act as mentors to cancer patients suffering from psychological or emotional difficulties, providing sympathy, information and support. External researchers will develop an education curriculum and service protocol for cancer patient psychological counseling, as well as a pilot application and evaluation of the developed protocols. In the second half of 2022, All.Can Korea will host a forum to discuss interim achievements and policy applicability. In addition, All.Can Korea will conduct patient leader mentoring pilot sessions for cancer patients as a follow-up project, targeting institutions such as All.Can Korea, local health centers, regional cancer centers, and integrated support centers for cancer survivors.










# Norway

#### **Achievements 2021**

After a successful launch in 2020, All. Can Norway used the year 2021 to move forward as an influencer in the Norwegian cancer debate. The effort has been put towards strengthening both awareness and political leverage around its new platform.





- Prehabilitation a more effective preparation of patients that leads to better results
  of treatment and quicker rehabilitation, and includes physical activity, diet, quit
  smoking and gaining more knowledge; and
- **Reliable & safe discharge** looking at what cancer patients should expect when being discharged from the hospital, and involving a home care programme.

Throughout the year, All.Can Norway has been present with a clear voice, both on social media and at various events, podcasts, physical and digital seminars. The collaboration with the Norwegian organization "Cancer Compass" (Kreftkompasset) for the launch of the book "Life after Cancer" resulted in a large amount of attention. The book was distributed at a roadshow during which 11 hospitals were visited, with the goal was to create awareness and ensure that a maximum number of cancer patients receive the book.



#### Outlook 2022

In 2022 the ambition is to take All.Can Norway to the next level. The National Initiative wants to use its new position and network to put a more patient-centric debate on the agenda. The vision for the work in 2022 is to utilise the platform "Prehabilitation and Reliable & safe discharge" and to leverage on a holistic approach on 'patient quality perception'. In order to raise, and at the same time explain, the concept of 'patient quality perception', All.Can Norway's plan is to conduct patient focus groups to get answers to questions such as 'What does the concept of patient-perceived quality mean to me?' and 'What are we missing and what do we need?'









# **Poland**

#### **Achievements 2021**

In 2021, All.Can Poland published two reports on changes that may lead to the improvement of standards of oncology care:



- 'Optimizing the financing model of diagnostic and treatment in terms of the patient's path and the results of treatment basing on lung cancer'
- 'Standards of patient service as part of the treatment in breast cancer units', which was prepared in collaboration with the Polish Society of Oncologists.

Both reports have been disseminated among decision-makers from the Polish Ministry of Health and Parliament, and were medialised and promoted in social media channels. Furthermore, the project on the standards of service in breast cancer units (BCU) has been also presented to directors of oncology hospitals.

#### Outlook 2022

Moving into 2022, All.Can Poland plans to further promote the process approach to management of cancer units based on its report "Standards of patient service as part of the treatment in breast

cancer units". Local workshops for oncology hospital management will be organised throughout the year.



Together with the Polish Society of Oncologists, the Polish Society of Pharmacoeconomy and the National Consultants in Hospital Pharmacy, All.Can Poland will work on a project "Optimising the use of hospital drugs" which has gained an initial positive reaction of the Ministry of Health. The recommendations will be promoted to decision-makers and hospital managers in order to inspire changes leading to better use of hospital drugs.





# **Spain**

#### **Achievements 2021**

In the light of the post pandemic context, All.Can Spain reactivated the platform with an ambitious plan to engage in a multi-stakeholder dialogue with prestigious and transversal health and cancer-related institutions, as well as plans to secure its mid and long-term sustainability. Therefore in 2021, All. Can Spain focused its efforts on reaching out to industry, patient groups, scientific societies, and health institutions such as the Royal National Academy of Medicine or Fundación ECO for the Excellence and Quality in Oncology, some of the most relevant institutions in Spain.

The relaunch of All.Can Spain was done in consultation and alignment with All. Can International as well as with the initial phase of All.Can Spain. To do so, a Position Paper was developed with a view to engage stakeholders and define ourgovernance dynamics for ctivities moving forward. The position paper crucially outlines, a set of governance rules for the Spanish chapter, securing transparency and agility in the decision-making process of the platform.

#### Outlook 2022:

In the 1st half of 2022, All.Can Spain expects to formally adhere further members (following the outreach undertaken in 2021) as well as put in place a Scientific Committee which will produce a report on inefficiencies in cancer care in Spain, with the participation of the Royal Academy of Medicine, Fundación ECO and the rest of the institutions and the patients associations,. In the 2nd half of the year, the report will be presented in a National Forum held in the Royal Academy of Medicine, and subsequently be disseminated throughout the Government Executive and the Legislative to seek the implementation implement actions over the inefficiencies detected. It will also be widely distributed through the media.









# **Sweden**

#### **Achievements 2021**

All.Can Sweden carried out various activities in 2021, despite the continued challenges with planning events due to the pandemic. Throughout the year, All.Can Sweden worked continuously in five different committees focused on the following themes: planning the high-level seminar, communications, the cancer stigma, equal access to care, and life after treatment.

As part of the committee work, a set of priorities and policy suggestions for equal access to cancer care ("Jämlik cancervård") has been created. The National Initiative also made suggestions for four policy points for avoiding the stigma around cancer, and developed two infographics that were published in nation-wide cancer magazines to promote awareness. Moreover, All.Can Sweden conducted a patient survey that provided valuable data to help the initiative in its work towards more efficient cancer care in Sweden.

All.Can Sweden concluded that the topic of data policy and patient data is highly relevant and important, and decided to make it the focus of the upcoming year. Also for that reason, patient data was the theme of All.Can Sweden's high-level seminar that was held in December. Moderated by All.Can Sweden's president, Emma Henriksson, the webinar included high-level speakers such as the government's Life Science Coordinator Jenni Nordborg, who has actively raised the topic of precision medicine at national level and promoted an infrastructure that will allow for early diagnosis through the implementation of new technology, and Professor Henrik Grönberg, who was appointed cancer researcher of 2022 for his ground-breaking research in early discovery of prostate cancer, as well as Matt Hickey, member of All.Can International.

#### Outlook 2022:

In 2022, All.Can Sweden will focus on two committee groups to work more efficiently on the most pressing issues that have been identified. One group will focus on data and continue to work on a clear framework for data to promote the development, of, for example, precision medicine. The other group will concentrate on 'the person behind the diagnosis' and be responsible for events and material associated with the cancer stigma, equal access to cancer care and the life after treatment.









# **Switzerland**

#### **Achievements 2021**

In 2021, All.Can Switzerland launched a project aimed at developing an outpatient oncology network in the canton of Grisons, a rural area in Switzerland. The project's goal is that in defined patient groups, nurseguided consultations of outpatients and oncological patients take place. Several benefits for both patients and the healthcare system are expected, such as increased patient satisfaction through accelerated processes and appointments planned in off-peak times. Also, nursing skills will be further developed, and the attractiveness of the profession increased.

All.Can Switzerland also grew its membership and network further, welcoming several new members from different areas of Swiss cancer care in 2021. In addition, the National Initiative has entered into partnerships with three initiatives from the Swiss healthcare sector: the Do Tank santeneXt, the platform ayacancersupport.ch for young cancer patients, and the DearMamma campaign to raise breast cancer awareness.

On 29 September, All.Can Switzerland supported a webinar on value based cancer care hosted by fmc, which featured top-class speakers and was attended by 80 participants from different areas of healthcare. In October, a small group of selected stakeholders from the health and cancer sectors were

invited to discuss the results of the Needs Assessment Study, which was commissioned by All.Can Switzerland and conducted in 2019/2020 under the lead of the Institute of Public Health from the University of Geneva.

#### Outlook 2022:

In 2022, All.Can Switzerland will concentrate on the

implementation of results from previous projects, such as disseminating the exciting findings of previous activities via dialogue formats and stakeholder discussions with the aim to initiate change and launch concrete measures to improve cancer care. The National Initiative will also focus on patient benefits and empowering the patient voice by sustainably strengthening it in the Swiss healthcare system, especially in the field of oncology. Under the leadership of the Patient Engagement Working Group, an internal project is to be developed that will decisively advance patient representation in the field of cancer.








# **United Kingdom**

#### **Achievements 2021**

In 2021, All.Can UK's work focused on taking forward the recommendations from its 2020 report 'All.Can



To raise awareness of the wider recommendations from the report, All.Can UK also worked in partnership with the Health Service Journal (HSJ), a leading healthcare publication in the UK, to host a roundtable and author three articles. The roundtable brought together a diverse group of clinicians, system leaders and third sector representatives, who explored the value of services for cancer patients and NHS staff wellbeing and discussed how to deliver this most effectively. The partnership will see the delivery of three All.Can UK articles on the HSJ's website, including two thought leadership pieces. A first article focusing on the important link between staff wellbeing and meeting patient needs has already been published, and a summary of the roundtable is due to be released in early 2022.

Moreover, All.Can UK has met with parliamentarians, health system leaders and patient groups, and shared a series of tweets posted on the All.Can International account throughout the year to promote the report recommendations.

#### Outlook 2022:


In 2022, All.Can UK expand its work to improve recognition of the important role that the third sector and health charities play in supporting patients' mental health needs. This will be achieved by gathering data and qualitative case studies from All. Can UK Working Group members on patient experience to build a business case for commissioning of psychosocial support services.

All.Can UK will also work to analyse data on cancer patient experience and quality of life to identify inequalities and specific areas of unmet need at a regional level. Task and Finish Groups will explore inequalities across areas such as protected characteristics, cancer types and geographic locations, and insights and recommendations will be taken to system and political stakeholders.

Lastly, the National Initiative will continue to disseminate the recommendations of the 2020 All.Can UK report using existing and newly developed assets to drive awareness raising of the need for enhanced psychosocial support for cancer patients.







All.Can International Rue du Luxembourg 22-24 BE-1000 Brussels Tel: +32 2 761 66 73


secretariat@all-can.org www.all-can.org

Twitter: @AllCanGroup

LinkedIn: All.Can

Facebook: @AllCanGroup

All.Can International is a not-for-profit organisation (ASBL) registered in Belgium. Its work is made possible with financial support from Bristol Myers Squibb (sustaining partner) and Roche, MSD, Johnson & Johnson, Baxter and Illumina (funding members).



 $\bigoplus$